Skip to main content

Corticosteroids in Urology

Corticosteroids are used in six discrete urologic domains: perioperative antiemesis and analgesia (ERAS), metastatic castration-resistant prostate cancer (abiraterone co-administration, steroid switch, standalone secondary hormonal therapy), renal-transplant immunosuppression and rejection treatment, contrast-allergy premedication for urologic imaging, interstitial cystitis / bladder pain syndrome with Hunner lesions, and investigational adjunctive medical-expulsive therapy for distal ureteral stones.[1][9][16][19][25][27] Each role has its own agent preference, dose, and evidence profile.

This article is the drug-class pharmacology hub, covering agents, doses and indication-by-indication evidence. Perioperative stress dosing of the chronic-steroid-using patient, adrenal-crisis recognition and treatment, and the wound-healing consequences of chronic steroids on urethroplasty, prosthetic or bowel-anastomotic reconstruction are covered separately at Perioperative steroids.

For the topical / intralesional counterparts see High-potency topical corticosteroids (genital LS, vulvar dermatoses) and Intralesional corticosteroids (urethral-stricture adjunct, keloids).

Agent Selection at a Glance​

AgentRelative anti-inflammatory potencyDurationTypical urologic dose / routeBest-supported indication
Dexamethasone30–60× hydrocortisone36–72 h (long-acting)4–8 mg IV single dose; 0.5 mg PO dailyPONV prophylaxis; mCRPC steroid switch [39][36][10]
Methylprednisolone~5× hydrocortisone12–36 h250–500 mg IV pulse daily × 3 d; 32 mg PO at 12 and 2 h before contrastAcute cellular rejection; contrast premed [39][20][16]
Prednisone~4× hydrocortisone12–36 hAbiraterone regimen depends on cancer setting / formulationGlucocorticoid co-administration with selected prostate-cancer treatments; not routine long-term IC/BPS therapy
Deflazacort~3× hydrocortisone12–36 hStudied off label in small stone trialsNot established routine MET
Hydrocortisone1× (reference)8–12 hStress dosing only; for major surgery in a patient at risk of glucocorticoid-induced adrenal insufficiency, ESE/ES 2024 suggests 100 mg IV at induction then 200 mg/24 h[39]Adrenal-insufficiency coverage — see Perioperative steroids

1. Dexamethasone — Perioperative Antiemesis and Analgesia​

PONV prophylaxis is the commonest perioperative use in urologic surgery — particularly after laparoscopic or robotic nephrectomy, prostatectomy, pyeloplasty, and any case with steep Trendelenburg.

QuestionAnswerEvidence
Dose4–8 mg IV, usually at induction, as one component of risk-based PONV preventionFifth Consensus Guidelines (2025) and earlier dose meta-analysis; assess glucose and cumulative steroid exposure. In pooled RCTs, 8–10 mg showed no clear advantage over 4–5 mg[2][36]
TimingAt inductionStandard
CombinationDex + 5-HT₃ antagonist (ondansetron) > 5-HT₃ alone for laparoscopic casesSom 2016 meta — OR 0.38; NNT 6.6[3]
PADDI substudyDex 8 mg IV did not significantly reduce clinically significant PONV on day 1 or 2 (RR 0.79; 95% CI 0.56–1.11) but reduced day-2 severe PONV (RR 0.58; NNT ≈ 37); across all 8,880 PADDI patients it lowered nausea scores, vomiting and rescue antiemetic useCorcoran 2022[4]

Perioperative analgesia / ERAS incorporation​

  • > 0.1 mg/kg IV reduces pain scores at rest and with movement at ≤ 4 h and 24 h with opioid-sparing effect (De Oliveira 2011 meta, 24 RCTs, n = 2,751).[5]
  • Dose-subgroup comparisons in the 2011 review did not demonstrate greater benefit above 0.2 mg/kg.[5]
  • High dose (dexamethasone ≥ 0.2 mg/kg or ≥ 15 mg, or an equivalent systemic glucocorticoid) (Laconi 2024 meta, 47 RCTs, n = 3,943) — rescue opioid use lower by 10 mg oral-morphine-equivalents; OR 0.29 for PONV; modest VAS reduction at 24 h (−6.18 mm at rest, −8.86 mm with movement; below the review's 10-mm threshold for clinical relevance, non-obese adults); no detected increase in pooled major AEs (OR 0.88) in the studied patients and operations.[6]
  • Postoperative sore throat. In a 14-RCT review of 1,837 tracheally intubated patients undergoing mixed operations, dexamethasone reduced sore throat at 24 hours (nine trials, 1,090 patients; OR 0.44) and hoarseness (six trials, 833 patients; OR 0.42). The ≥0.2 mg/kg subgroup had a sore-throat OR of 0.33; the review authors recommended this dose within 30 minutes of induction for nonpregnant patients without diabetes or corticosteroid contraindications.[7]
  • Peripheral nerve block prolongation — perineural or IV dexamethasone has been studied as an adjunct.[8] Perineural administration is off label.[8]

Safety — single-dose perioperative dexamethasone​

PADDI 2021 randomized 8,880 adults having nonurgent noncardiac surgery lasting at least two hours, with a skin incision >5 cm and an overnight stay, to dexamethasone 8 mg IV or placebo; 8,678 had the primary SSI assessment.[35] Infection occurred in 8.1% versus 9.1%, meeting the prespecified 2-percentage-point noninferiority margin.[35] Results were similar in the diabetes subgroup. PONV was reduced (42.2% versus 53.9%); hyperglycemic events in patients without diabetes were more frequent (0.6% versus 0.2%).[35] In a prespecified PADDI analysis of 8,478 modified intention-to-treat patients undergoing nonurgent noncardiac surgery, the single 8-mg dexamethasone dose[35] was followed by surgical-wound pain at six months in 491/4,258 (11.5%) versus 404/4,220 (9.6%) after placebo (RR 1.20; 95% CI 1.06–1.41).[46]

The older Polderman Cochrane review included 37 studies overall; its infection analysis used 26 studies / 4,603 participants and found probably little or no difference (Peto OR 1.01; 95% CI 0.80–1.27). Delayed wound healing remained uncertain (eight studies / 1,072; OR 0.99, 95% CI 0.28–3.43), and higher-risk patients were inadequately represented in the evidence.[1] It also documented transient glucose increases.[1][48]

Diabetes and hyperglycemia​

Dexamethasone raises glucose within hours. In a preplanned as-treated PADDI analysis of 1,130 patients with diabetes and HbA1c <9%, median peak 24-hour glucose was 12.5 versus 10.3 mmol/L after 8 mg dexamethasone versus placebo (estimated difference 1.86 mmol/L); SSI occurred in 11.1% versus 14.4% (RR 0.74; 95% CI 0.54–1.01).[40] Additional insulin was given to 26.6% versus 20.0% (P = 0.21), and hypoglycemia occurred in 0.8% versus 0.9%.[40] The Cochrane review found a mean rise of about 13 mg/dL in patients without diabetes and 32 mg/dL in the two small studies in diabetes (very low-certainty evidence).[1] Check glucose at the usual perioperative intervals, and treat the rise rather than withholding an indicated antiemetic. Patients with poorly controlled diabetes (HbA1c > 9%) were excluded from PADDI.[40] See Diabetes.

Higher-dose, repeated dexamethasone​

PACMAN randomized 1,222 adults over 50 undergoing major noncardiac surgery to dexamethasone 0.2 mg/kg at the end of surgery and on day 1 versus placebo. The 14-day composite of complications or death was not significantly reduced (17.0% versus 19.9%; adjusted OR 0.81; 95% CI 0.60–1.08), with no excess adverse events overall.[41]

Label cautions​

The dexamethasone sodium phosphate injection label warns that corticosteroids can mask signs of infection, lists impaired wound healing and increased insulin or oral hypoglycemic requirements in diabetes among adverse reactions, and advises gradual dose reduction to limit secondary adrenocortical insufficiency after prolonged use.[42]

Wound healing and vitamin A​

In a 72-rat wound-cylinder experiment, methylprednisolone lowered wound-fluid TGF-β and IGF-I and tissue collagen deposition.[43] In rat models, retinoids partially reversed methylprednisolone-impaired healing.[43] Perioperative vitamin A for patients on chronic steroids rests on this animal and older experimental work; clinical benefit is not established by trials. Chronic-steroid effects on reconstruction are covered on Perioperative steroids.

2. Corticosteroids in Metastatic Castration-Resistant Prostate Cancer​

The most nuanced use of corticosteroids in urology, and the one most often changing at the reconstructive urology and uro-oncology interface.

Abiraterone co-administration — required to prevent mineralocorticoid excess​

Abiraterone blocks CYP17; adrenal cortisol synthesis then drops, compensatory ACTH rises, and mineralocorticoid excess (HTN, hypokalemia, edema) follows. Concurrent glucocorticoid suppresses the ACTH drive.[9] In a randomized phase 2 study of 164 men with mCRPC receiving abiraterone, 24/34 evaluable men on prednisone 5 mg twice daily had no grade ≥1 hypokalemia or grade ≥2 hypertension through 24 weeks, versus 14/38 on prednisone 5 mg once daily.[47]

US product-label regimens. Zytiga is taken at 1,000 mg once daily on an empty stomach (no food for two hours before or one hour after the dose)[9]; Yonsa is taken at 500 mg once daily with or without food.[37] Their abiraterone doses, food instructions and accompanying glucocorticoids differ, and the products are not interchangeable solely by changing the steroid.[9][37]

SettingRegimen
Standard abiraterone + prednisone (CRPC)Prednisone 5 mg PO BID [9]
Zytiga + prednisone (metastatic high-risk CSPC)Prednisone 5 mg PO daily [9]
Fine-particle abiraterone (Yonsa)Methylprednisolone 4 mg PO BID [37]

The prednisone → dexamethasone "steroid switch" at progression​

When mCRPC progresses on abiraterone plus prednisone, a switch to abiraterone plus dexamethasone 0.5 mg daily has produced PSA responses in selected clinically stable patients with limited progression.[10]

StudynPSA₃₀PSA₅₀Outcome
SWITCH phase II (Romero-Laorden 2018)2646.2%34.6%Median biochem PFS 5.3 mo; radiologic PFS 11.8 mo; Exploratory ctDNA AR-gain association with non-response[10]
Yang 2021 (retrospective, China)13046.2%29.2%PFS 5.0 mo, OS 18.7 mo; Exploratory clinical predictors[11]
AbiDex (UK, Muller 2022; retrospective meeting abstract)33—12/33 (36%)24/33 (73%) had a “rebound biochemical response.” Median bPFS was 9 mo on AA+P versus 19 mo for the sequential AA+P then AA+D course (reported HR 0.28).[12]

Proposed mechanisms: long-term prednisone may drive resistance via glucocorticoid-receptor (GR) activation; the GR has substantial overlap with AR DNA-binding sites and can rescue expression of AR-regulated genes.[13][14] AR point mutations activated by glucocorticoids may additionally cause steroid-specific resistance.[14]

Glucocorticoids as standalone secondary hormonal therapy​

  • In chemotherapy-naïve CRPC, prednisolone 5 mg twice daily and dexamethasone 0.5 mg daily had different confirmed PSA response estimates: 22% and 41%, respectively, by intention to treat in a small randomized phase 2 trial (p = 0.08).[15] The 24% estimate applied to evaluable prednisolone recipients, not both agents.[14][15]
  • Venkitaraman 2015 randomized phase 2 (82 men). Confirmed PSA responses in the intention-to-treat comparison were 41% versus 22% for daily dexamethasone versus prednisolone (p = 0.08). The 47% versus 24% result (p = 0.05) was restricted to evaluable patients.[15]
  • COU-AA-302 placebo arm: 24% achieved a ≥ 50% PSA decline on prednisone plus placebo; 16% of patients with measurable disease had a RECIST objective response.[14][45]

Chemotherapy co-administration​

Corticosteroid co-administration and taxane premedication depend on the exact oncology regimen. Do not independently omit maintenance prednisone on an infusion day; reconcile it with dexamethasone and adrenal-risk coverage through the treating team.[14]

The critical caveat — glucocorticoids as disease drivers​

GR-mediated resistance is a mechanistic concern, not a reason to abruptly stop a required steroid. Reassess progressing disease with oncology; abiraterone-associated mineralocorticoid excess and adrenal insufficiency after steroid interruption remain clinical risks. Any steroid switch or taper must fit the complete treatment plan.[9][14]

3. Methylprednisolone in Renal Transplantation​

Induction and maintenance. Standard triple immunosuppression is tacrolimus plus antimetabolite (mycophenolate) plus low-dose glucocorticoids. Adequate tacrolimus exposure with low-dose glucocorticoids and antimetabolite is central to preventing early acute rejection and de novo donor-specific antibodies.[19]

Suspected acute rejection requires transplant-team assessment and usually biopsy, unless biopsy would substantially delay necessary treatment. KDIGO 2009 recommends corticosteroids initially for acute cellular rejection .[20] IV methylprednisolone 250–500 mg daily for three days is described as common practice; the optimal dose and duration have not been established by randomized trials. The regimen depends on histology, severity and response.[20][21]

Persistent histologic inflammation in older studies does not justify a universal rule to wait five days before escalating treatment. Clinical graft dysfunction and biopsy findings guide reassessment. Resistant or recurrent cellular rejection may require lymphocyte-depleting therapy; antibody-mediated rejection requires a distinct, individualized regimen. Do not apply a blanket 60–70% response estimate or automatic steroid / plasmapheresis / IVIG combination to every rejection type.[19][20][22]

Early steroid withdrawal: Woodle 2021 followed a randomized cohort of low- to moderate-immune-risk recipients without delayed graft function or first-week rejection, receiving tacrolimus and mycophenolate. At median 15.8 years, there was no detected difference in allograft failure from any cause including death (adjusted HR 0.83; 95% CI 0.62–1.10).[23] A 2026 Cochrane update found that steroid avoidance may increase biopsy-proven acute rejection by one year (RR 1.58; 95% CI 1.11–2.25; 10 studies, 1,845 recipients; low-certainty evidence) and may reduce post-transplant diabetes up to five years (RR 0.70; 95% CI 0.59–0.84; 13 studies, 2,390 recipients; low-certainty evidence). No rejection increase was detected in the subgroup receiving tacrolimus, an antimetabolite and induction therapy.[44]

4. Contrast-Allergy Premedication​

For prior immediate reactions to intravenous iodinated contrast, the 2025 ACR/AAAAI consensus uses reaction severity. The 2026 ACR Manual has broader eligibility language, permitting consideration of premedication after a prior allergic-like or unknown-type reaction to the same contrast class without this severity split.[16][17][18]

  • Mild immediate reaction: premedication is not recommended; switch the culprit agent when feasible.
  • Moderate immediate reaction: switch when feasible; premedication may be considered.
  • Severe immediate reaction. Consider alternative imaging first. If no acceptable alternative exists and harms from premedication or diagnostic delay are small, switch the iodinated contrast agent when feasible and premedicate; perform the study in a hospital with personnel and equipment to treat anaphylaxis. Consider allergist referral before future nonurgent imaging.[17]

This is not a blanket protocol for gadolinium, physiologic reactions or an “iodine / shellfish allergy” label. An isolated delayed reaction to iodinated contrast does not warrant premedication; a prior severe cutaneous adverse reaction to iodinated contrast calls for strict avoidance of iodinated contrast.[17] Record the agent, reaction and timing; prophylaxis does not eliminate anaphylaxis risk.

When an elective oral regimen is selected, the ACR Manual 2026 lists:[16]

RegimenTiming before contrast
Prednisone 50 mg PO13 h, 7 h and 1 h
Methylprednisolone 32 mg PO12 h and 2 h
Diphenhydramine 50 mg, if used1 h; the manual considers this adjunct optional

An accelerated IV regimen takes 4–5 hours; shorter courses have not demonstrated efficacy. If delay is unsafe, radiology and the treating team should agree on alternatives or monitored contrast administration with resuscitation capability. Consider hyperglycemia, sedation from antihistamines and diagnostic delay when deciding whether to premedicate.[16]

5. Prednisone in Interstitial Cystitis / Bladder Pain Syndrome​

AUA 2022 (Statement 26; Recommendation, Evidence Strength Grade C) advises against long-term systemic glucocorticoids as primary IC/BPS treatment. It rests on two observational studies with fewer than 30 patients combined, in which 47% to 64% responded, and on serious adverse events including new or worsened diabetes.[25] Its discussion states that the recommendation does not preclude short-term glucocorticoids for a flare.[25]

Soucy 2005 reported improvement in a small uncontrolled refractory-ulcerative-IC series. Hunner-lesion treatment and selected refractory disease should follow the dedicated bladder-directed pathway; intralesional triamcinolone is distinct from systemic prednisone.[25][26]

For the full IC/PBS framework including intravesical therapy, see the class-level IC/PBS clinical article and the intravesical IC/BPS agents hub.

6. Corticosteroids as MET Adjunct for Distal Ureteral Stones​

Small trials have studied off-label corticosteroids with α-blockers for distal stone expulsion:

  • Porpiglia 2006 (prospective; allocation by one of four treating urologists): 114 patients with symptomatic distal stones ≥5 mm were enrolled and 111 completed treatment. Tamsulosin 0.4 mg plus deflazacort 30 mg daily for 10 days yielded expulsion in 28/33 (84.8%), versus 18/30 (60%) with tamsulosin, 9/24 (37.5%) with deflazacort, and 8/24 (33.3%) with analgesics alone (p < 0.001 for the combination against the other groups).[27]
  • This trial did not establish benefit from deflazacort monotherapy (37.5% expulsion versus 33.3% with analgesics)[27]

EAU 2026 notes combination-study signals but its recommendation is to offer α-blockers for selected distal stones 5–10 mm. Balance infection, glucose and other steroid risks; analgesia and urgent drainage indications take priority.[38]

7. Niche Applications​

  • Post-ureteroscopy pain/inflammation. In Hamidi’s retrospective matched-pair analysis (72 methylprednisolone recipients and 72 controls after uncomplicated unstented URS), steroid use was associated with lower pain scores on POD0 (3.3 vs 3.9, p = 0.012) and POD1 (2.8 vs 3.4, p = 0.02), and with fewer renal-colic episodes (4.2% vs 13.2%, p = 0.036) and less parenteral analgesic use (18 vs 36 mg, p = 0.009) on POD0. The latter differences were not significant on POD1.[24]
  • Fournier gangrene. Not standard; management is surgical debridement, broad-spectrum antibiotics and resuscitation.[29][30] A historical case report involving necrotizing vasculitis is not evidence for treating infectious Fournier gangrene with immunosuppression or delaying source control. Steroid use for a separately established inflammatory disease or shock has a different indication.[28]
  • Idiopathic segmental ureteritis. Case report of successful prednisolone treatment of bilateral idiopathic segmental ureteritis after ureteral stenting failed.[31]
  • Ureteral stent-related symptoms. α-blockers are supported options for stent-related symptoms; corticosteroids have no established routine role for this indication in the cited evidence. Patient factors (age, depression, chronic pain) drive stent-symptom intensity more than surgical factors.[32][33][34]

Cross-Reference — What's Covered on the Perioperative Steroids Page​

To avoid duplication, the following sit at Perioperative steroids:

TopicWhere it lives
Chronic-steroid patient identification (who is at risk of adrenal crisis)Perioperative steroids
Stress-dose regimens by surgical complexity (minor / moderate / major)Perioperative steroids
Adrenal-crisis recognition and treatmentPerioperative steroids
Wound-healing consequences of chronic steroids on urethroplasty / prosthetics / bowel anastomosisPerioperative steroids
Preop mitigation (taper before elective reconstruction)Perioperative steroids
Dexamethasone 4–8 mg at induction[36] as an adjunctBrief on both pages — this article for drug-class pharmacology and evidence, perioperative page for the OR workflow including interaction with stress-dose coverage

Practical Pearls​

  • Single-dose dexamethasone 4–8 mg is a PONV option. PADDI supports SSI safety for one 8-mg dose; monitor glucose and avoid extending that conclusion to chronic or repeated high-dose exposure.[35][36]
  • Reconcile steroid indications and total exposure. Coordinate adrenal replacement and PONV prophylaxis with anesthesia rather than adding or omitting steroids reflexively.
  • mCRPC steroid switching is oncology-directed. Small studies show PSA responses in selected patients.[9][10][11][12]
  • Treat transplant rejection according to phenotype and response. Do not delay specialist reassessment until an arbitrary fifth day.[20]
  • Contrast premedication is selective. Correct methylprednisolone timing is 12 h and 2 h; consider the 2025 severity-based consensus before ordering any regimen.[16][17]
  • Long-term systemic steroids are not recommended for IC/BPS; routine steroid MET is not established.[25][38]
  • For stress dosing, adrenal crisis and chronic-steroid wound effects, use Perioperative steroids.

See Also​

References​

1. Polderman JA, Farhang-Razi V, Van Dieren S, et al. "Adverse side effects of dexamethasone in surgical patients." Cochrane Database Syst Rev. 2018;11:CD011940. doi:10.1002/14651858.CD011940.pub3

2. De Oliveira GS, Castro-Alves LJ, Ahmad S, Kendall MC, McCarthy RJ. "Dexamethasone to prevent postoperative nausea and vomiting: an updated meta-analysis of randomized controlled trials." Anesth Analg. 2013;116(1):58–74. doi:10.1213/ANE.0b013e31826f0a0a

3. Som A, Bhattacharjee S, Maitra S, Arora MK, Baidya DK. "Combination of 5-HT3 antagonist and dexamethasone is superior to 5-HT3 antagonist alone for PONV prophylaxis after laparoscopic surgeries: a meta-analysis." Anesth Analg. 2016;123(6):1418–1426. doi:10.1213/ANE.0000000000001617

4. Corcoran TB, Martin C, O'Loughlin E, et al. "Dexamethasone and clinically significant postoperative nausea and vomiting: a prespecified substudy of the randomised Perioperative Administration of Dexamethasone and Infection (PADDI) trial." Br J Anaesth. 2022;129(3):327–335. doi:10.1016/j.bja.2022.05.018

5. De Oliveira GS, Almeida MD, Benzon HT, McCarthy RJ. "Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials." Anesthesiology. 2011;115(3):575–588. doi:10.1097/ALN.0b013e31822a24c2

6. Laconi G, Coppens S, Roofthooft E, Van De Velde M. "High dose glucocorticoids for treatment of postoperative pain: a systematic review of the literature and meta-analysis." J Clin Anesth. 2024;93:111352. doi:10.1016/j.jclinane.2023.111352

7. Jiang Y, Chen R, Xu S, et al. "The impact of prophylactic dexamethasone on postoperative sore throat: an updated systematic review and meta-analysis." J Pain Res. 2018;11:2463–2475. doi:10.2147/JPR.S172419

8. Pehora C, Pearson AM, Kaushal A, Crawford MW, Johnston B. "Dexamethasone as an adjuvant to peripheral nerve block." Cochrane Database Syst Rev. 2017;11:CD011770. doi:10.1002/14651858.CD011770.pub2

9. ZYTIGA (abiraterone acetate): US prescribing information, revised November 2024. Label. Accessed September 12, 2026.

10. Romero-Laorden N, Lozano R, Jayaram A, et al. "Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH Study)." Br J Cancer. 2018;119(9):1052–1059. doi:10.1038/s41416-018-0123-9

11. Yang Z, Ni Y, Zhao D, et al. "Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone." BMC Cancer. 2021;21(1):919. doi:10.1186/s12885-021-08670-2

12. Muller D, Leaper A, Yadollahi S, et al. "AbiDex: retrospective UK analysis of steroid switching in patients with progression of mCRPC treated with abiraterone acetate." J Clin Oncol. 2022;40(6 Suppl):114. doi:10.1200/JCO.2022.40.6_suppl.114

13. Teo MY, Scher HI. "Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)." Br J Cancer. 2018;119(9):1041–1043. doi:10.1038/s41416-018-0239-y

14. Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G. "Sequencing of agents in castration-resistant prostate cancer." Lancet Oncol. 2015;16(6):e279–e292. doi:10.1016/S1470-2045(15)70033-1

15. Venkitaraman R, Lorente D, Murthy V, et al. "A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer." Eur Urol. 2015;67(4):673–679. doi:10.1016/j.eururo.2014.10.004

16. American College of Radiology. ACR Manual on Contrast Media. 2026. Patient selection and preparation chapter. Manual.

17. Wang C, Ramsey A, Lang D, et al. "Management and prevention of hypersensitivity reactions to radiocontrast media: a consensus statement from the American College of Radiology and the American Academy of Allergy, Asthma & Immunology." Radiology. 2025;315(2):e240100. doi:10.1148/radiol.240100

18. Wang C, Ramsey A, Lang D, et al. "Management and prevention of hypersensitivity reactions to radiocontrast media: a consensus statement from the ACR and AAAAI." J Allergy Clin Immunol Pract. 2025. doi:10.1016/j.jaip.2025.01.042

19. Hariharan S, Israni AK, Danovitch G. "Long-term survival after kidney transplantation." N Engl J Med. 2021;385(8):729–743. doi:10.1056/NEJMra2014530

20. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. "KDIGO clinical practice guideline for the care of kidney transplant recipients." Am J Transplant. 2009;9(Suppl 3):S1–S155. doi:10.1111/j.1600-6143.2009.02834.x

21. Bock HA. "Steroid-resistant kidney transplant rejection: diagnosis and treatment." J Am Soc Nephrol. 2001;12(Suppl 17):S48–S52. doi:10.1681/asn.v12suppl_1s48

22. Mazzucchi E, Lucon AM, Nahas WC, et al. "Histological outcome of acute cellular rejection in kidney transplantation after treatment with methylprednisolone." Transplantation. 1999;67(3):430–434. doi:10.1097/00007890-199902150-00016

23. Woodle ES, Gill JS, Clark S, et al. "Early corticosteroid cessation vs long-term corticosteroid therapy in kidney transplant recipients: long-term outcomes of a randomized clinical trial." JAMA Surg. 2021;156(4):307–314. doi:10.1001/jamasurg.2020.6929

24. Hamidi N, Ozturk E, Yikilmaz TN, Atmaca AF, Basar H. "The effect of corticosteroid on postoperative early pain, renal colic and total analgesic consumption after uncomplicated and unstented ureteroscopy: a matched-pair analysis." World J Urol. 2018;36(6):979–984. doi:10.1007/s00345-018-2210-1

25. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

26. Soucy F, Grégoire M. "Efficacy of prednisone for severe refractory ulcerative interstitial cystitis." J Urol. 2005;173(3):841–843. doi:10.1097/01.ju.0000153612.14639.19

27. Porpiglia F, Vaccino D, Billia M, et al. "Corticosteroids and tamsulosin in the medical expulsive therapy for symptomatic distal ureter stones: single drug or association?" Eur Urol. 2006;50(2):339–344. doi:10.1016/j.eururo.2006.02.023

28. Schultz ES, Diepgen TL, von den Driesch P, Hornstein OP. "Systemic corticosteroids are important in the treatment of Fournier's gangrene: a case report." Br J Dermatol. 1995;133(4):633–635. doi:10.1111/j.1365-2133.1995.tb02719.x

29. Montrief T, Long B, Koyfman A, Auerbach J. "Fournier gangrene: a review for emergency clinicians." J Emerg Med. 2019;57(4):488–500. doi:10.1016/j.jemermed.2019.06.023

30. Hagedorn JC, Wessells H. "A contemporary update on Fournier's gangrene." Nat Rev Urol. 2017;14(4):205–214. doi:10.1038/nrurol.2016.243

31. Atsuta T, Shimizu Y, Masuda N, et al. "First report of idiopathic segmental ureteritis successfully treated by steroid therapy." Int J Urol. 2012;19(6):583–586. doi:10.1111/j.1442-2042.2012.02968.x

32. Koprowski C, Kim C, Modi PK, Elsamra SE. "Ureteral stent-associated pain: a review." J Endourol. 2016;30(7):744–753. doi:10.1089/end.2016.0129

33. Betschart P, Zumstein V, Piller A, Schmid HP, Abt D. "Prevention and treatment of symptoms associated with indwelling ureteral stents: a systematic review." Int J Urol. 2017;24(4):250–259. doi:10.1111/iju.13311

34. Harper JD, Desai AC, Maalouf NM, et al. "Risk factors for increased stent-associated symptoms following ureteroscopy for urinary stones: results from STENTS." J Urol. 2023;209(5):971–980. doi:10.1097/JU.0000000000003183

35. Corcoran TB, Myles PS, Forbes AB, et al. "Dexamethasone and surgical-site infection." N Engl J Med. 2021;384(18):1731–1741. doi:10.1056/NEJMoa2028982

36. Gan TJ, Jin Z, Ayad S, et al. "Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting: Executive Summary." Anesth Analg. 2026;143(3):497–513. doi:10.1213/ANE.0000000000007816

37. YONSA (abiraterone acetate): US prescribing information. Primary source. Accessed September 12, 2026.

38. EAU Guidelines on Urolithiasis 2026. Medical expulsive therapy. Primary source. Accessed September 12, 2026.

39. Beuschlein F, Else T, Bancos I, et al. "European Society of Endocrinology and Endocrine Society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency." J Clin Endocrinol Metab. 2024;109(7):1657–1683. doi:10.1210/clinem/dgae250

40. Bach LA, Martin C, MacIsaac RJ, et al. "The effect of intraoperative dexamethasone on glycaemic responses in people with diabetes mellitus: a preplanned analysis of the Perioperative ADministration of Dexamethasone and Infection trial." Br J Anaesth. 2026;137(2):460–469. doi:10.1016/j.bja.2026.05.009

41. Asehnoune K, Le Moal C, Lebuffe G, et al. "Effect of dexamethasone on complications or all cause mortality after major non-cardiac surgery: multicentre, double blind, randomised controlled trial." BMJ. 2021;373:n1162. doi:10.1136/bmj.n1162

42. Dexamethasone sodium phosphate injection (Micro Labs Limited): US prescribing information. DailyMed. Accessed September 24, 2026.

43. Wicke C, Halliday B, Allen D, et al. "Effects of steroids and retinoids on wound healing." Arch Surg. 2000;135(11):1265–1270. doi:10.1001/archsurg.135.11.1265

44. Oliveras L, Melilli E, Cruzado JM, et al. "Steroid avoidance or withdrawal for kidney transplant recipients." Cochrane Database Syst Rev. 2026;5(5):CD005632. doi:10.1002/14651858.CD005632.pub4

45. Ryan CJ, Smith MR, de Bono JS, et al. "Abiraterone in metastatic prostate cancer without previous chemotherapy." N Engl J Med. 2013;368(2):138–148. doi:10.1056/NEJMoa1209096

46. Corcoran TB, Martin C, O'Loughlin E, et al. "Dexamethasone and persistent wound pain: a prespecified analysis of the randomised Perioperative Administration of Dexamethasone and Infection (PADDI) trial." Br J Anaesth. 2023;131(1):93–103. doi:10.1016/j.bja.2023.03.031

47. Attard G, Merseburger AS, Arlt W, et al. "Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study." JAMA Oncol. 2019;5(8):1159–1167. doi:10.1001/jamaoncol.2019.1011

48. Toner AJ, Ganeshanathan V, Chan MT, Ho KM, Corcoran TB. "Safety of perioperative glucocorticoids in elective noncardiac surgery: a systematic review and meta-analysis." Anesthesiology. 2017;126(2):234–248. doi:10.1097/ALN.0000000000001466